# [http://www.euromonitor.com Euromonmitor International]
# [http://www.bccresearch.com BCC Research]
# [http://www.ibisworld.com/ IBISWorld Industry Research]
# [http://www.marketresearch.com MarketResearch.com]
# [http://www.frost.com/prod/servlet/frost-home.pag Frost and Sullivan]
# Included two major markets namely U S and Japan.
# Study covers leading brands for Acne treatment for OTC and not Prescription drugs for mass distribution channel that includes mainstream supermarkets, chain drugstores and mass merchandisers.
=Global Acne Medications Market=
As per BCC Research the value of the Global Acne Medications Market for year 2012 was estimated to be $3.5 billion and it is expected to reach $4.5 billion by year 2018 at a CAGR of 2.8%.
[[Image:BCC ACNE.jpg|center|thumb|center|632px * 341px|Source:BCC Research,[http://www.marketresearch.com/BCC-Research-v374/Skin-Disease-Treatment-Technologies-Global-7616658]]]
{|border="0" cellspacing="0" cellpadding = "0" width="100%"
|align = "center"|<font color="#282828"><font size = "4">'''The Acne Product Pipeline'''</font></font>
|-
|}
{|border="2" cellspacing="0" cellpadding="4" width="100%" align="center"
|align = "center"|<br>''' ''' '''Product'''
|align = "center"|''' '''<br>'''Company'''
|align = "center"|<br>''' Indication'''
|align = "center"|<br>'''Development Status'''
|-
|ACAT Inhibitor
|Graceway Pharmaceuticals
|Acne
|Phase II
|-
|ANT-1207 (botulinum toxin A)
|Anterios
|Acne vulgaris
|Phase II
|-
|ASC-J9
|AndroScience
|Acne vulgaris
|Phase II
|-
|AUS-131/doxycycline
|Nexgen Dermatologics
|Acne vulgaris
|Phase I/II
|-
|BLI-1100
|Braintree Laboratories
|Acne vulgaris
|Phase II
|-
|CD-07223
|Galderma R &D
|Acne
|Phase II
|-
|CD-2475-101
|Galderma Laboratories
|Acne vulgaris
|Phase I
|-
|Clindamycin/tretinoin topical combination
|Skinvisible Pharmaceuticals
|Acne
|In clinical trials
|-
|COL-177
|Onset Dermatologics
|Acne vulgaris
|In clinical trials
|-
|Duac Topical Gel low-dose clindamycin/benzoyl peroxide gel
|Stiefel, a GSK company
|Acne vulgaris
|Application submitted
|-
|E-0301
|Elorac
|Acne
|Phase III
|-
|IDP 107
|Valeant Pharmaceuticals
|Acne vulgaris
|Phase II
|-
|Isotretinoin
|Cipher Pharmaceuticals
|Acne
|Phase III
|-
|JNJ-10229570
|Johnson & Johnson
|Acne vulgaris
|Phase II
|-
|Metvixia
|PhotoCure methyl aminolevulinate
|Acne
|Phase II
|-
|NB-003 (nanoemulsion)
|NanoBio
|Acne
|Phase I
|-
|NVC-422
|Galderma
|Acne
|Phase I completed
|-
|Tazarotene foam (retinoid foam)
|Stiefel, a GSK company
|Acne vulgaris
|Phase III
|-
|Tretinoin topical
|Phosphagenics
|Acne
|Phase I
|-
|WC-3018
|Warner Chilcott
|Acne
|Phase II
|-
|WC-3035
|Warner Chilcott
|Acne
|Phase I
|-
|}<br clear="all">
{|border="0" cellspacing="0" cellpadding = "0" width="100%"
|<font color="#282828"> Source: [http://www.phrma.org/sites/default/files/pdf/skindiseases2011.pdf Pharmaceutical Research and Manufacturers of America, 2011]
== '''USA market study''' ==
===Historic Sales===
* Anti-acne products sold through mass retail channels totaled $646 million in The Acne Treatment Manufacturing OTC industry has maintained strong growth during the past five years. As per IBIS World estimates from 2007 to account for about 4% 2012, revenue has grown steady, and it is expected to grow at an average annual rate of all cosmeceutical sales. Subtracting these products from total sales translates to growth from $122.4 billion in 2001 % to $152.6 3 billion in 2005—still a 6% CAGR. * The sales figures are of OTC products only and not prescription drugs.
The sales figures are for Mass Channel (Mass channel includes mainstream supermarkets* Because acne-prone individuals consider treatment products a necessary expense, chain drugstores and mass merchandisers) revenue continued to rise during the recession, though growth did slow as consumers switched to more inexpensive products.
* Increasing prevalence of adult-onset and persistent acne conditions has given rise to new, targeted products and an expanded consumer base, another factor that has aided revenue growth during the period.
[[Image:Anti Acne Treatment market* In 2012, industry revenue is expected to maintain its growth, gaining 2.jpg|700px|thumb|center|[http://academic.marketresearch.com/product/display.asp?productid=1658180&curl=&surl=7%2Fsearch%2Fresultsduring the year, due to modest improvements in per capita disposable income.asp%3Fprid%3D925717062%26query%3Dthe%2BU.S.%2Bcosmeceuticals%2Bmarket%26cmdgo%3DGo&prid=925717062 Source]]]
===Major Players in Acne Space===[[Image:USACNE2012.jpg|center|thumb|center|632px * 341px|Source:IBIS World,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html]]]
J&J commanded over 47% of anti-acne preparation sales in 2007. About 27 points of that share was yielded by the Neutrogena brand and another 16 points by Clean & Clear. J&J’s closest rival was Reckitt Benckiser, which had only a 15% share, thanks to its early 2006 acquisition of Boots Healthcare and its time-honored Clearasil brand. ===Industry Forecast===
Share * From 2012 to 2017, industry revenue is expected to go up an annualized rate of U3.S1% to $2. Retail Dollar Sales 7 billion from current level of Anti-Acne Preparations in Mass Channels for 2007 are shown below$2.3 billion. Mass Channel (Mass channel includes mainstream supermarkets* Improving economic conditions is likely to drive the market, chain drugstores and mass merchandisersas greater disposable income growth allows consumers to spend on higher-priced over-the-counter (OTC)items.
Various Channels of Distribution:
[[Image:US2018 acne.jpg|center|thumb|center|632px * Mass channel includes mainstream supermarkets341px|Source:IBIS World, chain drugstores and mass merchandisers[http://www. ibisworld.com/industry/acne-treatment-manufacturing-otc.html]]] ===Major Players in Acne Space===* Prestige includes upscale-priced department stores As per IBIS World estimates the top three industry players (eJohnson & Johnson, Guthy-Renker and Reckitt-Benckiser) hold a combined market share of about 68.g1%, in 2012.The rest of the market is characterized by a large number of small and medium-size businesses. * J&J (Neutrogena, Bloomingdale'sClean & Clear, Nordstrom)Aveeno, beauty chains (SephoraAmbi), brandcommanded over 28.8% of anti-dedicated stores (Avedaacne preparation sales in 2012. J&J’s closest rival was Guthy Renker, M(Proactiv Solutions) which had a 24.A6% share followed by Reckitt Benckiser at 14.C7%.), salons and spas with retail counters, etc.* Online Stores* Direct Sales
[[Image:Major PlayersUS Acne Share.jpg |700pxUS Acne Share.jpg|thumb|center|632px * 341px|Source:IBIS World,[http://academicwww.marketresearchibisworld.com/productindustry/displayacne-treatment-manufacturing-otc.asp?productid=1658180&curl=&surl=%2Fsearch%2Fresults.asp%3Fprid%3D925717062%26query%3Dthe%2BU.S.%2Bcosmeceuticals%2Bmarket%26cmdgo%3DGo&prid=925717062 Sourcehtml]]]
===Consumer Target Group & Product Categorization===